ASH) annual meetings are two of the largest conferences in the fields of hematology and oncology. These meetings are attended by physicians, researchers, pharmaceutical industry colleagues, and representatives from the media and business sectors. The intention of both societies, as stated in their submission guidelines, is to accept abstracts that have not previously been presented. These policies are presumably in place to minimize redundancy and, due to time and space constraints, allow the largest number of researchers to present their findings. Hence, we asked, are there duplicative presentations at these two large meetings, and if so, how often do they occur?
METHODS-WHAT WE DID:
To date, however, the success of the societies in eliminating duplication has not been carefully analyzed. In addition, the motivations behind re-presentation have not been evaluated objectively. Therefore, we conducted a review of 327 malignant hematology (non-transplantation) abstracts presented at ASCO 2010 and compared them with prior and subsequent ASCO and ASH meetings to evaluate the incidence of duplicate presentations and their relationship to funding sources over a 2 year time frame.
RESULTS-WHAT WE FOUND:
Our analysis indicated that 31% of accepted abstracts were duplicated during the 2-year time frame, with those indicating pharmaceutical support three times more likely to be duplicated ( Figure 1 ).
IMPLICATIONS FOR PRACTICE & LIMITATIONS OF DATA:
These findings suggest that a substantial number of duplicative abstracts are re-presented, with a disproportionate number having pharma sponsorship. The motivations for duplication are varied but may include an influence of pharma marketing strategies. Although these results are limited by our search strategy and to this 2-year time frame, the results were similar when we analyzed ASH and ASCO 2014 leukemia abstracts. These findings demonstrate the need for a more effective abstract selection system and that further study of the role of marketing in large meetings such as ASCO and ASH would be appropriate. 
Methods
All abstracts presented at ASCO 2010 in the area of malignant hematology were compared with abstracts from ASCO and ASH 2009 and ASH 2010, and funding sources were reviewed.
Results
More than half (54%) of all abstracts submitted to ASCO 2010 acknowledged pharmaceutical company support. Almost one third (31%) of ASCO 2010 abstracts were resubmitted in the 2-year time period, and it was notable that a high fraction (75%) of these duplicate abstracts had pharmaceutical industry sponsorship, compared with 42% of the abstracts that were submitted only once.
Conclusion
Despite current guidelines prohibiting duplicate abstract presentation, a substantial proportion (31%) of abstracts at large international hematology-oncology meetings are duplicative, with potential negative consequences. In addition, a disproportionate percentage of the duplicate abstracts rely on pharmaceutical industry support (75%), suggesting that marketing strategies may be a motivation for some of these repetitive submissions. The motivations for duplicate presentation have not been carefully analyzed. Although they may provide a means for investigators to introduce their research to new listeners and/ or to reinforce it to those with prior exposure, repetitive presentations may also serve as a marketing tool for companies and have the potential to decrease the information pool by limiting the presentation of other novel ideas because of time and space constraints. We therefore reviewed the abstracts from four consecutive ASH and ASCO meetings between 2009 and 2010 to assess the prevalence of duplicate presentations and evaluate whether funding relationships affected this behavior.
INTRODUCTION

METHODS
We reviewed non-stem-cell transplantation, malignant hematology abstract acceptances at the annual ASH and ASCO meetings from 2009 to 2010. All relevant abstracts listed on the ASCO 2010 Web site were reviewed and then cross referenced with abstracts presented at the 2009 ASCO meeting and the 2009 and 2010 ASH meetings. ASCO 2010 was used as the reference point for identifying duplicates, because it permitted comparisons with three other relatively contemporaneous meetings. Using the search engines of each organization, a search strategy based on authors' names and title keywords was used. A duplicate abstract was defined as any submission that had been presented $ two times that did not contain significant modifications of efficacy or toxicity data or conclusions. Subset analyses and periodic updates were considered duplicative if there were no substantial modifications of the results section. All abstracts were then assessed for sponsorship. Abstracts disclosing research funding from pharmaceutical companies or that included authors with leadership positions or employment in pharmaceutical companies associated with the abstract content were considered to be industry sponsored. All others, including those in which authors disclosed a consultant or advisory role, stock ownership, honoraria, expert testimony, or other remuneration, were not considered to be industry funded. Lastly, the abstracts were examined for type of initial and repeat presentations (oral, poster, or publication only). Among the 103 duplicate abstracts, 75% (78 of 103) indicated pharmaceutical support. Thus, a duplicate abstract was approximately 33 more likely to have industry support than not (75% v 25%), whereas only 42% (96 of 224) of nonduplicate abstracts mentioned industry sponsorship. Furthermore, only 16% of abstracts without industry support were submitted more than once. One hundred (97%) of the 103 duplicate abstracts were presented at least once as an oral or poster presentation; 41% (42 of 103) were presented $ three times, with eight of these presented at all four meetings. A vast majority (85 [83%] of 103) of duplicate submissions were selected to be presented in either an oral or poster format on $ two occasions, with 60% (62 of 103) of duplicate abstracts presented at least once as an oral presentation. Of the remaining 18 abstracts, 15 were presented as a poster or oral presentation once, and three abstracts were repeated in publication form only.
DISCUSSION
A majority (53%) of abstracts submitted to the ASCO meeting in 2009 used industry support, demonstrating the large and critical role that the pharmaceutical industry has in hematologic clinical trials and drug development. A substantial percentage (31%) of malignant hematology abstracts presented or published at the ASCO meeting in 2010 were identified as being duplicative of abstracts submitted or presented at prior or subsequent consecutive ASCO or ASH meetings. Duplicate abstracts were 33 more likely to be industry funded than not (75% v 25%), were almost twice as likely to be industry funded than abstracts that were which were not duplicated (75% v 42%), and were usually chosen to be presented in an oral format (60%). This is notable, because oral presentations are the preferred platform used to highlight the most significant submissions and are therefore often well attended. It is in these venues that both the ability to disseminate important novel information and the ability to advertise findings are likely to have the most impact.
To assess whether these patterns have changed in recent years, we also reviewed abstracts from the 2014 ASCO leukemia and myelodysplastic syndromes categories and compared these with abstracts presented at ASH 2014. We independently evaluated 108 abstracts and identified 23 abstracts (21%) as being duplicative. Concordance between each author's assessments was excellent. Once again, it was noted that almost half (44%) of the abstracts as well as 74% of the duplicate abstracts acknowledged pharmaceutical company support. These findings are similar to the larger 2009 to 2010 analysis and suggest that duplicate submissions remain common and may be preferentially sponsored by the pharmaceutical industry.
Our search methodology used ASCO 2010 as the reference point from which all duplicate abstracts were identified. This strategy may have overlooked repeat abstract acceptances that occurred during this period but did not include ASCO 2010. For instance, during our review, a substantial number (minimum,24) of ASH 2009 and ASH2010 abstracts wereidentified as duplicative. However, because ASH-ASH abstracts were not reviewed systematically, these were not included in our analysis. In addition, alterations of titles or authors in serial abstracts may have impeded our ability to identify all duplicate presentations and funding entities. For instance, repetitive abstracts frequently omitted the name of a search keyword used in the initial abstract title or added or deleted authors in sequential abstracts. Therefore, our calculations likely underestimate the full scope of duplicate publications.
The role of industry support of abstract sponsorship, although substantial, may also be underestimated. ASH and ASCO policies rely on investigators to provide full disclosure, and our analysis only included mention of employment or leadership positions or research funding as evidence of industry sponsorship. Abstracts disclosing other forms of remuneration, such as consultant or advisory roles or other funding, were not considered to be industry sponsored, despite the potential for authors to have a stake in the success of the presented information. Disclosure requirements can also be confusing, and it is left to the authors to determine whether their compensation satisfies the criteria for disclosure and, if so, to which category it belongs. It was not uncommon for an individual author's conflict of interest (COI) disclosures to vary between sequential abstract publications, reflecting the confusing nature of this process or the possibility that many authors do not take this requirement particularly seriously. Of note, several studies evaluating the interpretation of research associated with COIs have demonstrated that such work is viewed with a higher degree of skepticism than research without associated COIs. [4] [5] [6] It is unknown whether this consideration influences some researchers to minimize their disclosures despite the stated requirements. In addition, parent company-subsidiary company relationships were at times unclear, and it was not unusual to find parent companies listed as funding entities in abstracts involving the product of a subsidiary or vice versa. This ambiguity could cloud the reader's ability to identify the relationship between a funding entity and the subject of a given abstract. Nevertheless, we are confident that our search methodology was sufficient to capture the overwhelming majority of the relevant information.
The motivations for duplicate submissions are diverse and include academic pressure to publish, pressures felt by pharmaceutical companies to ensure that their work is financially rewarded, and pressures on meeting organizers and the societies to develop an agenda that interests a diverse audience, which includes researchers, clinicians, patients, the general public, and the pharmaceutical industry (and by extension business and investing community). The marketing benefit garnered by companies as a result of repetitive presentations is unknown but may be considerable when data are presented effectively at large international meetings to a highly selected target audience.
There are also multiple incentives for academic physicians. Oral and poster presentations at national and international meetings are directly linked to academic recognition, promotions, and consequently income. The recognition garnered and the relationship with industry provide a gateway to other opportunities, such as additional grant funding, national and international speaking engagements, and invitations to advisory committees and speakers' bureaus. In addition, it is widely recognized that the abstract authors may not actually compose the abstract content, but rather, the drafts are prepared by the pharmaceutical companies or medical writing companies that the companies support financially. The incidence of this practice is not known. Access to the primary data is sometimes limited, and the timeframe for review and modification of the abstract is often quite brief. Moreover, it is common to rotate the authors so that the honor of presenting the data is shared from meeting to meeting. Pharmaceutical company sponsorship may lead to a bias against presenting negative results or alternatively spinning the results positively in the conclusion or title. 3, 7, 8 Indeed, one study evaluating this noted that in cancer research sponsored by nonprofit and forprofit organizations, unfavorable conclusions were reported 38% and 5% of the time, respectively. 9 In addition, it has been suggested that financial or consulting relationships could also produce overt or subliminal bias on the part of abstract reviewers and meeting organizers, which could influence final decisions about abstract presentation and choice of session.
10
This article focuses on duplicate presentations of hematologic malignancy research. However, it is evident that this practice occurs in other medical disciplines as well. Other publications have detailed the phenomenon of repetitive presentations at urology, orthopedic, and general surgery meetings. [11] [12] [13] These studies found duplicate abstract rates ranging between 4% and 20%. The higher percentage of repetitive abstract presentations we describe may reflect a greater reliance on pharmaceutical industry sponsorship in hematologic drug development compared with other medical specialties. 14 However, differences in the time periods examined, definitions of what constitutes duplication, and reviewer subjectivity limit direct comparison among fields. Interestingly, many of the publications in other fields also highlighted the prevalence of author and title modifications in duplicate abstracts. 13 Although duplicate presentations could limit opportunities to present other novel ideas, it also may have beneficial effects. It can be argued that duplicate presentations at ASH and ASCO target different audiences and therefore result in more effective dissemination of information. This could certainly be the case when data are represented at international meetings overseas, including the European Society of Medical Oncology and European Hematology Association. In addition, the size of ASH and ASCO makes it difficult for attendees to be present at all relevant presentations, and repeat presentations may allow interested parties to attend at subsequent meetings. However, other forms of publicizing this information are already used by both societies. Tumor-specific subspecialty meetings by ASCO and conference reviews offered by both ASCO and ASH, as well as regional meetings organized by universities and state societies, are plentiful and provide access to information for those who did not attend the national meetings. The accessibility of the abstracts as well as the actual presentations online also argues against the need for duplicate presentations. Furthermore, although periodic updates may be important, the frequency of the updates (every 6 months) and the lack of substantial changes in the data, coupled with the prominent degree of pharmaceutical sponsorship, suggest that marketing, rather than dissemination of new scientific findings, may be a motive in many instances. [14] [15] [16] Currently, both ASCO and ASH use independent abstract review panels, and part of their task is to minimize duplicate acceptances. However, based on our findings, it is clear that the current approach is imperfect. If national societies desire to eliminate or decrease duplicate presentations, the meeting organizers, abstract reviewers, and particularly the authors share the responsibility of evaluating the submissions more critically. Strategies could include use of software to identify repeat presentations, improvements to the COI process, and a requirement that previous presentations of the data be specifically mentioned in the submitted abstract. 
